PubMed Health⌕ Search

Biomedical subjects

Z H Yang

Publications and source records attributed to Z H Yang.

69 records · Page 4Linked to original sources

Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts.

Both the internal mammary artery and the saphenous vein are used to construct coronary-artery bypass grafts. We hypothesized that the release or production of endothelium-derived relaxing factor, which regulates blood flow and inhibits platelet function, may differ in venous and arterial grafts. We therefore studied endothelium-dependent relaxation in internal mammary arteries, internal mammary veins, and saphenous veins obtained from 58 patients undergoing coronary bypass surgery. Vascular rings with and without endothelium were suspended in organ chambers, and isometric tension was recorded. Acetylcholine (10(-8) to 10(-4) M), thrombin (1 U per milliliter), and adenosine diphosphate (10(-7) to 10(-4) M) evoked potent endothelium-dependent relaxation in the mammary artery but weak response in the saphenous vein (P less than 0.005; n = 6 to 27). In the mammary artery, relaxation was greatest in response to acetylcholine (86 +/- 4 percent reduction in norepinephrine-induced tension), followed by thrombin (44 +/- 7 percent) and adenosine diphosphate (39 +/- 8 percent). In the saphenous and mammary veins, relaxation was less than 25 percent. Relaxation was unaffected by indomethacin but was inhibited by methylene blue and hemoglobin (P less than 0.005 and 0.01, respectively), which suggests that endothelium-derived relaxing factor was the mediator. Endothelium-independent relaxation in response to sodium nitroprusside was similar in arteries and veins. We conclude that endothelium-dependent relaxation is greater in the mammary artery than in the saphenous vein. The possibility that this contributes to the higher patency rate among arterial grafts than among venous grafts will require further study.

Acetylcholine↗

Perfluorocarbon as blood substitute in clinical applications and in war casualties.

The results of infusion of fluorocarbon blood substitute (FCBS) in surgical patients (including war casualties) are presented. One hundred and forty patients (male 82, female 58, age 17-71 years) were infused with 200-1,000 ml of FCBS during operation. Fourteen cases were emergency operations because of trauma and/or hemorrhagic shock and 113 cases were selective operations. Thirteen cases were war casualties. Seventy-three patients also received 300-2,700 ml of banked blood. The vital signs and ECG received normal and blood pressure increased significantly (compared to pre-infusion P 0.01) during and after infusion. Hemoglobin and RBC values did not change significantly, however, WBC counts increased for a week. PaO2 increased significantly (P less than 0.05) compared with preinfusion or the control group (infused with same dose of HES). pH and PaCO2 did not change remarkably. Platelet count decreased transiently, but platelet function did not change, nor did coagulation function. Fibrinolysis was more active, but recovered in 24 hours. The decrease of CH50 was observed immediately after infusion and recovered in 72 hours. There was no change in hepatic and renal function; however, transient increase of SGPT was found in 3 cases. The results suggested that the FCBS had the capacity of carrying oxygen and expanding plasma volume. It is efficient to apply as an alternative to blood transfusion during operation in treatment of traumatic and/or hemorrhagic shock even in war casualties. Transient chest tightness and/or flushing were found in 5 cases at the beginning of the infusion, and disappeared when the infusion slowed down. Urticaria after infusion were observed in 2 cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro.

Several promising antiviral nucleosides have been tested in paired combinations against guinea pig cytomegalovirus (GPCMV) replication in guinea pig embryo (GPE) cells by plaque reduction assay; these are [9-(2-hydroxy-1-3-2-dioxaphosphorinan-5-yl)oxymethyl]-guanin e P-oxide (2'nor-cGMP, compound 164), [4-amino-5-bromo-7-(2-hydroxyethoxymethyl)-pyrrolo(2,3-d)pyrimidine] (compound 102), (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), 9-(2-hydroxyethoxymethyl)-guanine (acyclovir, ACV) and 3'-azido-3'-deoxythymidine (zidovudine, AZT). Various degrees of interactions were observed; i.e. synergistic reactions were noted in the presence of compound 164/compound 102 and compound 164/DHPG combinations at all concentrations tested. HPMPC/DHPG combinations were synergistic at relatively lower concentrations of DHPG, but became antagonistic as the concentration of DHPG increased. Combinations of compound 164/ACV and DHPG/AZT were antagonistic.

Animals↗